GAL1704 for Cheek Augmentation & Correction of Midface Contour

See also
Status	Clinical Trial	Phase
Completed	`NCT04534660` - Preliminary Safety and Effectiveness of SMI-01 as a Tissue Filler	N/A
Completed	`NCT03160716` - Injection Technique Assessment of Restylane Lyft With Lidocaine for Cheek Augmentation	N/A
Completed	`NCT04638816` - Study to Evaluate Satisfaction After Treatment With Restylane	N/A

See also

Status

Clinical Trial

Phase

Completed

NCT04534660 - Preliminary Safety and Effectiveness of SMI-01 as a Tissue Filler

N/A

Completed

NCT03160716 - Injection Technique Assessment of Restylane Lyft With Lidocaine for Cheek Augmentation

N/A

Completed

NCT04638816 - Study to Evaluate Satisfaction After Treatment With Restylane

N/A

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT03700047
Study type	Interventional
Source	Galderma R&D
Contact
Status	Completed
Phase	N/A
Start date	October 18, 2018
Completion date	May 22, 2020

GAL1704 for Cheek Augmentation and Correction of Midface Contour Deficiencies

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms